Company news
Tyra Biosciences, Inc. news in 2025
Tyra Biosciences, Inc.'s news releases, calls and decks from 2025, newest first.
Tyra Biosciences Strengthens Leadership Team with Appointments of Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer
November 30, 2025
Tyra Biosciences Announces Participation at Upcoming Investor Events
November 11, 2025
Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights
November 4, 2025
Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia
August 20, 2025
Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights
August 13, 2025
Tyra Biosciences Announces Fireside Chat on Achondroplasia and Growth Disorders at UBS Biotech Management Live Call Series
July 20, 2025
Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025
July 7, 2025
Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)
June 29, 2025
Tyra Biosciences to Participate at Upcoming Investor Conferences
May 11, 2025
Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights
May 7, 2025
Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights
March 26, 2025
Tyra Biosciences to Present at Upcoming Investor Conferences
February 10, 2025
Tyra Biosciences Announces Appointment of Adele Gulfo to Board of Directors
January 28, 2025
Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium
January 21, 2025
Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)
January 9, 2025